Skip to NavigationSkip to content

Roche's Tecentriq combo scoops up European approval in first-line metastatic lung cancer

Published on 08/03/19 at 09:45am

Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with Avastin (bevacizumab), paclitaxel and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC).

Further, the EC specified that this combination should only be used in patients with EGFR mutant or ALK-positive NSCLC after appropriate targeted therapies have failed.

The decision was supported by the submission of Phase 3 data drawn from 1,202 participants which demonstrated that Roche’s combo extended median overall survival by 19.8 months compared to 14.9 months with Avastin and chemotherapy alone in the intent-to-treat population. The combo also improved progression-free survival (PFS) by 41% compared to Avastin and chemotherapy, while overall response rate (ORR) stood at 56.4% of people compared to 40.2%.

“Today’s announcement makes the combination of Tecentriq, Avastin and chemotherapy available to people in Europe with advanced, non-squamous non-small cell lung cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “This approval includes EGFR mutant or ALK-positive non-small cell lung cancer after failure of a targeted therapy marking a first for this subgroup of patients, in which there is a significant need for alternative treatment options.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches